Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
UBS launched its first global brand campaign since 2009 today, reflecting the firm’s strategic transformation and future direction. Featuring a distinctive brand film as well as advertising with images by Annie Leibovitz, the campaign also refreshes the strong UBS brand with a contemporary look and feel. The external launch follows a three-month internal campaign that inspired unprecedented rates of employee engagement.
“The brand campaign is an expression of the successful strategic transformation UBS has undergone over the past four years,” said Sergio P. Ermotti, Group Chief Executive Officer. “Reflecting the strategic transformation through our branding gives us additional momentum.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7612551-ubs-launches-global-brand-campaign/
The Leukemia & Lymphoma Society (LLS), the world’s leading voluntary non-profit dedicated to blood cancers, released 30 “proof points” - one for each day of September, Blood Cancer Awareness Month - to demonstrate its impact on the cancer landscape and progress towards a world without blood cancers.
LLS has invested more than $1 billion in research to advance breakthrough therapies and cures for blood cancer patients. In many cases, those treatments are now helping patients with other cancers and chronic diseases. Due to its focus on blood cancers, survival rates are improving. Since the early 1960s, five-year survival rates for many blood cancer patients have doubled, tripled and even quadrupled.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554851-lls-blood-cancer-awareness-month/
This year, parents of nearly 16,000 children in the U.S. will hear the words: “Your child has cancer.” One in five of those children won’t survive. September is Childhood Cancer Awareness Month, and as a leader in the way the world understands, treats and defeats childhood cancer and other life-threatening diseases, St. Jude Children’s Research Hospital® will focus on raising awareness and funds for this very important issue.
Despite significant progress made by St. Jude Children’s Research Hospital, which has helped push the overall childhood cancer survival rates from 20 to more than 80 percent since the hospital opened in 1962, cancer remains the leading cause of death by disease for children over the age of 1. Each year about 175,000 children are diagnosed with cancer worldwide, and 60 percent of these kids don’t have access to modern treatment. For those who win their battles against childhood cancer, victory often comes at a cost as survivors face a much higher risk of experiencing unique long-term health effects later in life.
To view the multimedia release go to:
http://www.multivu.com/players/English/7390851-st-jude-hospital-childhood-cancer-awareness/
Texas Instruments (TI) (NASDAQ: TXN) today introduced the first all-in-one USB Type-C and USB Power Delivery (PD) controller, which integrates a port power switch and port data multiplexer. The TPS65982 USB PD controller is the only integrated circuit (IC) available that provides the full power path, operating as a Single- or Dual-Role Port and enabling a variety of host and device power implementations.
For applications requiring higher data rates, the TPS65982 can be combined with the 5.4-Gbps HD3SS460, the industry’s first USB Type-C cross-point switch. This solution enables USB connectors on either end of the cable to be flipped up or down, delivers power up to 100 W, and supports Alternate Modes to distribute video over DisplayPort from the host to the end device.
To view the multimedia news release visit
http://www.multivu.com/players/English/70647529-texas-instruments-usb-type-c/
eKonomics from PotashCorp, an online resource dedicated to providing farmers with relevant, easy-to-understand agricultural information, today unveils the first nationwide nutrient balance analysis highlighting a major nutrient application deficit across the United States. The analysis finds that soil nutrient removal rates continue to outpace fertilizer application in most states.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7555351-potashcorp-ekonomics-soil-fertilizer/
An estimated 15 million babies around the world are born premature each year and more than one million of them do not survive their early birth. Although the United States has seen sustained improvement in its preterm birth rate, it has one of the highest rates of preterm birth of any industrialized country.
Next month, organizations and individuals around the globe will observe Prematurity Awareness Month and World Prematurity Day. World-famous photographer Anne Geddes, and international superstars Thalia and Hilary Duff, will join other celebrity parents to spread the word that premature birth is a very serious health problem for babies worldwide.
To view the Multimedia News Release, go http://www.multivu.com/players/English/65164-march-of-dimes-march-for-babies-2014/
Chase Card Services, a division of JPMorgan Chase & Co. [NYSE: JPM], today announced the launch of the new Chase Ultimate RewardsSM website developed to meet the changing needs of Chase cardholders and deliver a more personalized experience. According to a recent survey Chase conducted in partnership with Mercator Advisory Group, 35 percent of consumers surveyed ranked an attractive rewards program ahead of other factors like interest rates and credit line when selecting which credit card to use most. Additionally, the survey found that 55 percent of consumers surveyed said that, as a rule, they try to use a credit card with rewards that are relevant to them.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7328251-chase-launches-new-website-offering-enhanced-personalized-rewards/
Half of the nation has been in a deep freeze with temperatures hovering around 0 degrees Fahrenheit and even more frigid when considering the wind chill. Schools are closing down and with a shortage of propane, rates are going sky high. Some are even going without food to heat their home. The thought of even going outside might be completely daunting. Here are some winter safety tips that will help you and your kids endure this winter. http://youtu.be/kbTQ1COc_4g
On Sunday, August 24, truth®, the nation’s largest and longest running youth smoking prevention campaign, premiered the latest advertisements in its new Finish It campaign, titled “Unpaid” and “Response”. Both aired during the hugely popular MTV Video Music Awards broadcast — an annual music awards ceremony that attracts millions of viewers and sparks immediate cultural conversations. Teen smoking rates are at their lowest levels in 22 years, and through the Finish It campaign, truth aims to enlist this generation to end smoking for good.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7304851-truth-launches-finish-it-campaign-challenges-teens-to-become-first-smoke-free-generation/
Data presented today at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia for the full trial period, and a significantly lower rate of severe hypoglycaemia during the maintenance period (defined as week 16 onwards) with Ryzodeg® compared to biphasic insulin aspart 30, both administered twice-daily1.
Ryzodeg® is the first combination of two distinct insulin analogues, Tresiba® (insulin degludec), the once-daily basal insulin with an ultra-long duration of action, and the well-established mealtime insulin NovoRapid® (insulin aspart), in the ratio of 70% and 30%, in one pen for people with type 2 diabetes2-4.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64158-ryzodeg-improved-glycaemic-control
